What the Research Shows
Research on Glutathione falls roughly into three groups. The first explains how the molecule works inside cells, and this part is solid. The second notices that levels are often lower in older people or in certain illnesses. The third, and least settled, asks whether raising those levels makes any practical difference.
The Foundations
- Naming the molecule (Biochem J, 1921): Hopkins describes a sulfur-containing substance in cells that is easily oxidised and restored, and calls it Glutathione.
- Making it from scratch (Biochem J, 1935): Harington and Mead synthesise it and settle its structure.
- A protective enzyme (J Biol Chem, 1957): Mills identifies glutathione peroxidase, which uses it to shield red blood cells.
- The selenium link (Science, 1973): Rotruck and colleagues show that this enzyme contains selenium.
- The big overview (Annu Rev Biochem, 1983): Meister and Anderson pull together decades of work on how it is made, used and moved around.
Modern Summaries
- More than an antioxidant (Biochem Pharmacol, 2003): a review arguing that Glutathione also takes part in cell signalling and, in some settings, can even promote oxidation.
- Roles and measurement (Mol Aspects Med, 2009): an overview of its protective jobs and of the pitfalls in measuring it accurately.
- Links with disease (Biol Chem, 2009): a review of how disturbed Glutathione balance is associated with many conditions, while noting that association is not proof of cause.
- How cells build it (Biochim Biophys Acta, 2013): a detailed look at the two-step synthesis and how it is controlled.
Supplying the Building Blocks
Because cells make their own Glutathione, some researchers test whether providing its raw materials helps. Two small studies from Baylor College of Medicine in 2011 found lower Glutathione production in older adults and in people with poorly controlled type 2 diabetes. In both groups, two weeks of extra cysteine and glycine in the diet brought production back up and lowered markers of oxidative stress. The studies were short and involved only a few dozen people.
Adding Glutathione Itself
- No change after four weeks (J Altern Complement Med, 2011): in healthy volunteers, a supplement did not shift markers of oxidative stress or Glutathione status compared with placebo.
- Higher stores after six months (Eur J Nutr, 2015): in a larger and longer trial, Glutathione levels in blood and other cells rose over time and fell back after people stopped.
- Cystic fibrosis (Am J Respir Crit Care Med, 2013): an inhaled form given for six months did not improve lung function compared with placebo.
- Parkinson’s disease, early trial (Mov Disord, 2015): a nasal spray was well tolerated over three months, which was the main question of that study.
- Parkinson’s disease, follow-up trial (J Parkinsons Dis, 2017): symptoms improved in every group, including placebo, and Glutathione did not beat placebo.
- Fatty liver (BMC Gastroenterol, 2017): in a small pilot study without a comparison group, a liver enzyme linked to damage went down; the authors called for proper controlled trials.
Reading These Results
Put together, the picture is cautious. The molecule clearly matters inside cells, and low levels often go hand in hand with illness. But trials that try to top up Glutathione have produced a mixture of small positive signals, neutral findings and placebo effects. Many studies measured blood markers rather than how people actually felt or recovered.
Gaps That Remain
- Size and length: most trials included fewer than a hundred people and lasted weeks or months.
- Getting it where it is needed: it is still debated how much Glutathione from outside reaches the inside of cells intact.
- Cause or consequence: low levels in disease may be a result of illness rather than a driver of it.
- Product quality: studies used carefully made materials, which say nothing about the quality of other products.
Bottom Line
Glutathione is one of the best-understood molecules in cell biology, yet attempts to use it as a remedy have so far produced modest and inconsistent results. Larger, longer and better-controlled studies are still needed.
References
- Hopkins FG. On an autoxidisable constituent of the cell. Biochem J. 1921;15(2):286-305. PMID 16742989
- Harington CR, Mead TH. Synthesis of glutathione. Biochem J. 1935;29(7):1602-1611. PMID 16745829
- Mills GC. Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown. J Biol Chem. 1957;229(1):189-197. PMID 13491573
- Rotruck JT, et al. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973;179(4073):588-590. PMID 4686466
- Meister A, Anderson ME. Glutathione. Annu Rev Biochem. 1983;52:711-760. PMID 6137189
- Pompella A, et al. The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol. 2003;66(8):1499-1503. PMID 14555227
- Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30(1-2):1-12. PMID 18796312
- Ballatori N, et al. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem. 2009;390(3):191-214. PMID 19166318
- Sekhar RV, et al. Glutathione synthesis is diminished in patients with uncontrolled diabetes and restored by dietary supplementation with cysteine and glycine. Diabetes Care. 2011;34(1):162-167. PMID 20929994
- Sekhar RV, et al. Deficient synthesis of glutathione underlies oxidative stress in aging and can be corrected by dietary cysteine and glycine supplementation. Am J Clin Nutr. 2011;94(3):847-853. PMID 21795440
- Allen J, Bradley RD. Effects of oral glutathione supplementation on systemic oxidative stress biomarkers in human volunteers. J Altern Complement Med. 2011;17(9):827-833. PMID 21875351
- Lu SC. Glutathione synthesis. Biochim Biophys Acta. 2013;1830(5):3143-3153. PMID 22995213
- Griese M, et al. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Am J Respir Crit Care Med. 2013;188(1):83-89. PMID 23631796
- Richie JP Jr, et al. Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr. 2015;54(2):251-263. PMID 24791752
- Mischley LK, et al. A randomized, double-blind phase I/IIa study of intranasal glutathione in Parkinson's disease. Mov Disord. 2015;30(12):1696-1701. PMID 26230671
- Mischley LK, et al. Phase IIb study of intranasal glutathione in Parkinson's disease. J Parkinsons Dis. 2017;7(2):289-299. PMID 28436395
- Honda Y, et al. Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. BMC Gastroenterol. 2017;17(1):96. PMID 28789631